8-KEarnings & ResultsExhibits & Filings

Merck & Co., Inc. 8-K Report, Financial Results (Aug 4, 2026)

Filed August 4, 2026For Securities:MRK

Summary

Merck & Co., Inc. (MRK) filed an 8-K on August 4, 2026, to report its second-quarter 2026 financial results and operations. The filing incorporates by reference a press release (Exhibit 99.1) detailing the company's earnings for the period and supplemental information (Exhibit 99.2) that provides further context. Investors should refer to these exhibits for the specific financial performance details, as the 8-K itself primarily serves as a notification and a vehicle for providing these results.

Key Highlights

  • 1Merck released its second-quarter 2026 financial results on August 4, 2026.
  • 2The 8-K filing includes a press release (Exhibit 99.1) with detailed earnings information.
  • 3Supplemental information (Exhibit 99.2) is also provided for a more comprehensive view.
  • 4The company has not elected to use the extended transition period for new or revised accounting standards.
  • 5This filing is furnished under Item 2.02 and Item 9.01(d) of the 8-K.
  • 6Information furnished is not deemed 'filed' for certain regulatory purposes unless specifically incorporated into other filings.

Frequently Asked Questions

The specific financial results for the second quarter of 2026 are detailed in the press release (Exhibit 99.1) and supplemental information (Exhibit 99.2) incorporated by reference into this 8-K filing.

This 8-K filing officially announces Merck's second-quarter 2026 earnings and operational performance to the public, incorporating the detailed financial statements and commentary from the accompanying press release and supplemental documents.

No, the information furnished under Item 2.02 in this 8-K, including the press release and supplemental information, is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it automatically incorporated by reference into other filings unless explicitly stated.

The filing indicates that Merck, as an emerging growth company, has not elected to use the extended transition period for complying with new or revised financial accounting standards.